Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M528Revenue (TTM) $M65.4Net Margin (%)-61.7Altman Z-Score24.2
Enterprise Value $M119EPS (TTM) $-0.3Operating Margin %-65.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-61.7Higher ROA y-yY
Price/Book1.310-y EBITDA Growth Rate %-34.7Quick Ratio29.9Cash flow > EarningsN
Price/Sales15.35-y EBITDA Growth Rate %-32.6Current Ratio29.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-9.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-9.5Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M137ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ACHN is held by these investors:

ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FISHERMAN JASON SDirector 2016-12-22Buy10,000$3.96-2.53view
Fenton Mary KayCFO 2016-12-05Buy2,500$4.11-6.08view
Truitt JosephChief Commercial Officer 2016-12-02Buy3,500$4.06-4.93view
MANNING MARTHA EEVP, General Counsel 2016-12-02Buy2,500$4.09-5.62view
Deshpande MilindCEO 2016-12-02Buy2,500$4.06-4.93view
Barrish Joel CChief Scientific Officer 2016-12-02Buy2,500$4.06-4.93view
Apelian DavidChief Medical Officer 2015-12-30Sell10,000$10.5-63.24view
Fenton Mary KayCFO 2015-12-28Sell43,500$10.08-61.71view
VITULLO NICOLEDirector 2015-11-11Sell550,000$10.17-62.05view
VITULLO NICOLEDirector 2015-09-25Sell9,310$8.22-53.04view

Quarterly/Annual Reports about ACHN:

News about ACHN:

Articles On GuruFocus.com
Steven Cohen Increases Position in Dynavax Oct 07 2016 
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 

More From Other Websites
Biotech Movers: Cempra Flys High On Phase Three Results Feb 24 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Feb 24 2017
Achillion reports 4Q loss Feb 23 2017
Achillion reports 4Q loss Feb 23 2017
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
ACHILLION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 23 2017
4:10 pm Achillion Pharma beats by $0.17, beats on revs; guides FY17 EPS below consensus Feb 23 2017
Achillion Reports 2016 Fourth Quarter and Year-End Financial Results Feb 23 2017
Biotech's Rally Continues to Build in 2017: Today's Reports on Achillion Pharmaceuticals and... Feb 22 2017
Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference Feb 13 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Feb 03 2017
Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen Feb 02 2017
Coverage initiated on Achillion Pharma by Ladenburg Thalmann Feb 02 2017
Blog Coverage FDA Approved Orphan Drug Designation for TG Therapeutics' Combination of TG-1101 and... Jan 25 2017
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : January 11, 2017 Jan 11 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Jan 10 2017
Where are the opportunities for investors in health care? Jan 09 2017
Achillion Receives $15M from J&J for HCV Study Enrolment Dec 29 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 28 2016
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for... Dec 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)